MARCOS BERRY, MD, URRUTIA LIONEL, MD, CRISTOBAL GUIXE, MD, RODRIGO VILLAGRAN, MD, HECTOR COÑOMAN, MD, PATRICIO LAMOZA, MD. Bariatric Surgical Unit, Clinica Las Condes, Santiago-CHILE
Introduction: The aim of this report is to present our experience in treating type 2 diabetic (T2DM) obese patients with LSG in reference to %EWL, metabolic performance after surgery and morbi-mortality.
Methods: Prospective case series of 20 obese well controlled type 2 diabetic patients who underwent LSG between April 2006 and August 2009 and who were followed with a specific protocol.
Results: Follow up 12 month (6 to 20 months) Total 20 patients.13 male and 7 females were operated. Mean preop BMI was 37 (31-51). Mean preop HbA1c was 6, 6% (5, 5-7,9). They were managed with oral medications. No patient was treated with insulin on a regular basis. At twelve month of follow-up (6-15 months) the mean BMI was 27.7, the %EWL was 80.7% in the same period, the mean postop HbA1c was 5,6%. The mean preop fasting glucose level was 128mg% (91-190) vs 91,7 mg (81-103). The preop mean fasting insulin level was 40 uU/ml (17-108) compared to 18 uU/ml at twelve months after SG. At twelve months, 19 patients had no farmacological treatment (95%) and 1 lowered the doses. 1 patient (5%) presented hemoperitoneum that was managed non operatively. No mortality. No conversions
Conclusions: LSG is a safe and effective treatment for the mild and well controlled T2DM obese patients with excellent metabolic control of their Diabetes. Longer follow up is needed.
Program Number: P071